Off the shelf CAR T shows stronger residual clearance in lymphoma Allogene Therapeutics said its off the shelf CAR T therapy cleared residual cancer cells in patients with B cell lymphoma at a rate about three times higher than standard care. CAR T treatments use a patient’s immune cells that have…
Continue reading...
Continue reading...